

## HR 4565

### Responsibility in Drug Advertising Act of 2016

**Congress:** 114 (2015–2017, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 12, 2016

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Feb 19, 2016)

**Official Text:** <https://www.congress.gov/bill/114th-congress/house-bill/4565>

## Sponsor

**Name:** Rep. DeLauro, Rosa L. [D-CT-3]

**Party:** Democratic • **State:** CT • **Chamber:** House

## Cosponsors

No cosponsors are listed for this bill.

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 19, 2016

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## Summary (as of Feb 12, 2016)

### Responsibility in Drug Advertising Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

## Actions Timeline

- **Feb 19, 2016:** Referred to the Subcommittee on Health.
- **Feb 12, 2016:** Introduced in House
- **Feb 12, 2016:** Referred to the House Committee on Energy and Commerce.